X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RTX-003 is a targeted anti-CD25 monoclonal antibody that binds CD25 without blocking IL-2 on the high-affinity IL-2 receptor alpha on T regulatory (T reg) cells, and designed to induce T reg cell death, thus supporting tumor immunity.
Lead Product(s): RTX-003
Therapeutic Area: Oncology Product Name: RTX-003
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: RubrYc Therapeutics
Deal Size: $6.0 million Upfront Cash: $1.0 million
Deal Type: Acquisition September 21, 2022
Details:
iBio has entered into its first Statement of Work under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.
Lead Product(s): Atbody-st-2
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: ATB Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2020
Details:
Under the terms of the agreement, iBio obtained an exclusive license to Planet’s ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.
Lead Product(s): ACE2-Fc
Therapeutic Area: Infections and Infectious Diseases Product Name: ACE2-Fc
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Planet Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 28, 2020
Details:
Early functional testing of mouse antisera from IBIO-201 immunized mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays.
Lead Product(s): IBIO-201
Therapeutic Area: Infections and Infectious Diseases Product Name: IBIO-201
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
IBM Watson Health has received interest in the offering from numerous hospitals, sponsors, contract research organizations and academic institutions, and is currently enabling 15 COVID-19 disease trials.
Lead Product(s): IBIO-200
Therapeutic Area: Infections and Infectious Diseases Product Name: IBIO-200
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: IBM Watson Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 24, 2020
Details:
The new subunit vaccine (“IBIO-201”) combines antigens derived from the SARS-CoV-2 spike protein fused with the Company’s patented lichenase booster molecule (“LicKM”), which is designed to enhance immune response.
Lead Product(s): IBIO-201
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
Under the MSAs, IDRI will support pre-clinical development and provide clinical trial oversight, while iBio will provide process development and manufacturing services to IDRI, as needed.
Lead Product(s): IBIO-200
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Infectious Disease Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 10, 2020
Details:
iBio plans to transfer its proprietary FastPharming Manufacturing System™ to AzarGen in South Africa for production of critical biological medicines for the African continent.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AzarGen Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 26, 2020
Details:
iBio created its proprietary VLP candidates using its FastPharming System™. then deployed this plant-based expression platform’s rapid production capabilities to deliver VLPs.
Lead Product(s): IBIO-200
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Texas A&M University System laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2020
Details:
iBio created its SARS-CoV-2 Virus-Like Particle-based constructs in just a few weeks using its FastPharming System™ to produce the nanoparticles in, and purify them from, plants.
Lead Product(s): SARS-CoV-2 Virus-Like Particle
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
